nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluocinonide—Secondary adrenocortical insufficiency—Ritonavir—acquired immunodeficiency syndrome	0.0385	0.0545	CcSEcCtD
Fluocinonide—Cushing's syndrome—Ritonavir—acquired immunodeficiency syndrome	0.0294	0.0416	CcSEcCtD
Fluocinonide—SERPINA6—blood plasma—acquired immunodeficiency syndrome	0.0271	0.0979	CbGeAlD
Fluocinonide—Leukoderma—Didanosine—acquired immunodeficiency syndrome	0.0268	0.0379	CcSEcCtD
Fluocinonide—SMO—skin of body—acquired immunodeficiency syndrome	0.0237	0.0854	CbGeAlD
Fluocinonide—SMO—spinal cord—acquired immunodeficiency syndrome	0.0174	0.0627	CbGeAlD
Fluocinonide—SMO—vagina—acquired immunodeficiency syndrome	0.0167	0.0604	CbGeAlD
Fluocinonide—SMO—lung—acquired immunodeficiency syndrome	0.0158	0.0571	CbGeAlD
Fluocinonide—Folliculitis—Nelfinavir—acquired immunodeficiency syndrome	0.0158	0.0223	CcSEcCtD
Fluocinonide—NR3C1—nerve—acquired immunodeficiency syndrome	0.0157	0.0567	CbGeAlD
Fluocinonide—SMO—nervous system—acquired immunodeficiency syndrome	0.0146	0.0529	CbGeAlD
Fluocinonide—SMO—central nervous system—acquired immunodeficiency syndrome	0.0141	0.0509	CbGeAlD
Fluocinonide—Folliculitis—Indinavir—acquired immunodeficiency syndrome	0.0127	0.018	CcSEcCtD
Fluocinonide—Eruption—Efavirenz—acquired immunodeficiency syndrome	0.0123	0.0174	CcSEcCtD
Fluocinonide—Folliculitis—Efavirenz—acquired immunodeficiency syndrome	0.012	0.017	CcSEcCtD
Fluocinonide—NR3C1—blood plasma—acquired immunodeficiency syndrome	0.0119	0.0429	CbGeAlD
Fluocinonide—Folliculitis—Delavirdine—acquired immunodeficiency syndrome	0.0115	0.0163	CcSEcCtD
Fluocinonide—SMO—brain—acquired immunodeficiency syndrome	0.0112	0.0404	CbGeAlD
Fluocinonide—SMO—lymph node—acquired immunodeficiency syndrome	0.0108	0.039	CbGeAlD
Fluocinonide—Folliculitis—Ritonavir—acquired immunodeficiency syndrome	0.0106	0.015	CcSEcCtD
Fluocinonide—Folliculitis—Saquinavir—acquired immunodeficiency syndrome	0.0102	0.0145	CcSEcCtD
Fluocinonide—SERPINA6—blood—acquired immunodeficiency syndrome	0.00993	0.0359	CbGeAlD
Fluocinonide—Skin exfoliation—Nevirapine—acquired immunodeficiency syndrome	0.00977	0.0138	CcSEcCtD
Fluocinonide—Folliculitis—Lamivudine—acquired immunodeficiency syndrome	0.00976	0.0138	CcSEcCtD
Fluocinonide—SERPINA6—bone marrow—acquired immunodeficiency syndrome	0.00961	0.0347	CbGeAlD
Fluocinonide—Glycosuria—Efavirenz—acquired immunodeficiency syndrome	0.00932	0.0132	CcSEcCtD
Fluocinonide—SERPINA6—lung—acquired immunodeficiency syndrome	0.00871	0.0314	CbGeAlD
Fluocinonide—Glycosuria—Ritonavir—acquired immunodeficiency syndrome	0.00824	0.0117	CcSEcCtD
Fluocinonide—SERPINA6—nervous system—acquired immunodeficiency syndrome	0.00807	0.0291	CbGeAlD
Fluocinonide—Dermatitis contact—Indinavir—acquired immunodeficiency syndrome	0.00789	0.0112	CcSEcCtD
Fluocinonide—SERPINA6—central nervous system—acquired immunodeficiency syndrome	0.00777	0.028	CbGeAlD
Fluocinonide—Skin exfoliation—Efavirenz—acquired immunodeficiency syndrome	0.00721	0.0102	CcSEcCtD
Fluocinonide—Hyperglycaemia—Amprenavir—acquired immunodeficiency syndrome	0.00707	0.01	CcSEcCtD
Fluocinonide—Skin exfoliation—Delavirdine—acquired immunodeficiency syndrome	0.00689	0.00975	CcSEcCtD
Fluocinonide—Dermatitis contact—Ritonavir—acquired immunodeficiency syndrome	0.0066	0.00934	CcSEcCtD
Fluocinonide—Dry skin—Stavudine—acquired immunodeficiency syndrome	0.00658	0.0093	CcSEcCtD
Fluocinonide—Swelling—Indinavir—acquired immunodeficiency syndrome	0.00657	0.0093	CcSEcCtD
Fluocinonide—Hyperglycaemia—Didanosine—acquired immunodeficiency syndrome	0.00644	0.00911	CcSEcCtD
Fluocinonide—SERPINA6—brain—acquired immunodeficiency syndrome	0.00616	0.0223	CbGeAlD
Fluocinonide—Swelling—Delavirdine—acquired immunodeficiency syndrome	0.00594	0.00841	CcSEcCtD
Fluocinonide—Hyperglycaemia—Nevirapine—acquired immunodeficiency syndrome	0.00579	0.00819	CcSEcCtD
Fluocinonide—NR3C1—skin of body—acquired immunodeficiency syndrome	0.00571	0.0206	CbGeAlD
Fluocinonide—Hyperglycaemia—Nelfinavir—acquired immunodeficiency syndrome	0.00561	0.00794	CcSEcCtD
Fluocinonide—Hyperglycaemia—Stavudine—acquired immunodeficiency syndrome	0.00559	0.00791	CcSEcCtD
Fluocinonide—Nasopharyngitis—Zidovudine—acquired immunodeficiency syndrome	0.00558	0.00789	CcSEcCtD
Fluocinonide—Hyperglycaemia—Abacavir—acquired immunodeficiency syndrome	0.00551	0.00779	CcSEcCtD
Fluocinonide—Dry skin—Indinavir—acquired immunodeficiency syndrome	0.00532	0.00752	CcSEcCtD
Fluocinonide—Nasopharyngitis—Efavirenz—acquired immunodeficiency syndrome	0.0049	0.00693	CcSEcCtD
Fluocinonide—Dry skin—Delavirdine—acquired immunodeficiency syndrome	0.0048	0.0068	CcSEcCtD
Fluocinonide—Immune system disorder—Nevirapine—acquired immunodeficiency syndrome	0.00464	0.00657	CcSEcCtD
Fluocinonide—NR3C1—lymphoid tissue—acquired immunodeficiency syndrome	0.00462	0.0167	CbGeAlD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Amprenavir—acquired immunodeficiency syndrome	0.00462	0.00653	CcSEcCtD
Fluocinonide—NR3C1—digestive system—acquired immunodeficiency syndrome	0.00457	0.0165	CbGeAlD
Fluocinonide—Hyperglycaemia—Indinavir—acquired immunodeficiency syndrome	0.00452	0.0064	CcSEcCtD
Fluocinonide—Immune system disorder—Nelfinavir—acquired immunodeficiency syndrome	0.0045	0.00636	CcSEcCtD
Fluocinonide—Erythema—Nevirapine—acquired immunodeficiency syndrome	0.00447	0.00633	CcSEcCtD
Fluocinonide—Dry skin—Ritonavir—acquired immunodeficiency syndrome	0.00444	0.00629	CcSEcCtD
Fluocinonide—Immune system disorder—Abacavir—acquired immunodeficiency syndrome	0.00442	0.00625	CcSEcCtD
Fluocinonide—Nervous system disorder—Amprenavir—acquired immunodeficiency syndrome	0.00437	0.00618	CcSEcCtD
Fluocinonide—NR3C1—blood—acquired immunodeficiency syndrome	0.00435	0.0157	CbGeAlD
Fluocinonide—Erythema—Nelfinavir—acquired immunodeficiency syndrome	0.00433	0.00613	CcSEcCtD
Fluocinonide—Skin disorder—Amprenavir—acquired immunodeficiency syndrome	0.00433	0.00612	CcSEcCtD
Fluocinonide—Dry skin—Saquinavir—acquired immunodeficiency syndrome	0.00428	0.00605	CcSEcCtD
Fluocinonide—Hyperglycaemia—Efavirenz—acquired immunodeficiency syndrome	0.00427	0.00604	CcSEcCtD
Fluocinonide—NR3C1—bone marrow—acquired immunodeficiency syndrome	0.00421	0.0152	CbGeAlD
Fluocinonide—NR3C1—spinal cord—acquired immunodeficiency syndrome	0.00419	0.0151	CbGeAlD
Fluocinonide—Hyperglycaemia—Delavirdine—acquired immunodeficiency syndrome	0.00409	0.00578	CcSEcCtD
Fluocinonide—Infection—Didanosine—acquired immunodeficiency syndrome	0.00403	0.00571	CcSEcCtD
Fluocinonide—NR3C1—vagina—acquired immunodeficiency syndrome	0.00403	0.0146	CbGeAlD
Fluocinonide—Nasopharyngitis—Lamivudine—acquired immunodeficiency syndrome	0.00398	0.00563	CcSEcCtD
Fluocinonide—NR3C1—lung—acquired immunodeficiency syndrome	0.00381	0.0138	CbGeAlD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Nevirapine—acquired immunodeficiency syndrome	0.00378	0.00535	CcSEcCtD
Fluocinonide—Hyperglycaemia—Ritonavir—acquired immunodeficiency syndrome	0.00378	0.00535	CcSEcCtD
Fluocinonide—Erythema—Zidovudine—acquired immunodeficiency syndrome	0.00375	0.00531	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Nelfinavir—acquired immunodeficiency syndrome	0.00366	0.00518	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Stavudine—acquired immunodeficiency syndrome	0.00365	0.00517	CcSEcCtD
Fluocinonide—Hyperglycaemia—Saquinavir—acquired immunodeficiency syndrome	0.00364	0.00515	CcSEcCtD
Fluocinonide—Immune system disorder—Indinavir—acquired immunodeficiency syndrome	0.00362	0.00513	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Abacavir—acquired immunodeficiency syndrome	0.0036	0.00509	CcSEcCtD
Fluocinonide—Nervous system disorder—Nevirapine—acquired immunodeficiency syndrome	0.00358	0.00507	CcSEcCtD
Fluocinonide—Skin disorder—Nevirapine—acquired immunodeficiency syndrome	0.00355	0.00502	CcSEcCtD
Fluocinonide—NR3C1—nervous system—acquired immunodeficiency syndrome	0.00353	0.0127	CbGeAlD
Fluocinonide—Pain—Didanosine—acquired immunodeficiency syndrome	0.00347	0.00491	CcSEcCtD
Fluocinonide—Hyperglycaemia—Lamivudine—acquired immunodeficiency syndrome	0.00347	0.00491	CcSEcCtD
Fluocinonide—Nervous system disorder—Stavudine—acquired immunodeficiency syndrome	0.00346	0.00489	CcSEcCtD
Fluocinonide—Infection—Abacavir—acquired immunodeficiency syndrome	0.00345	0.00488	CcSEcCtD
Fluocinonide—Skin disorder—Nelfinavir—acquired immunodeficiency syndrome	0.00344	0.00486	CcSEcCtD
Fluocinonide—Skin disorder—Stavudine—acquired immunodeficiency syndrome	0.00342	0.00484	CcSEcCtD
Fluocinonide—Immune system disorder—Efavirenz—acquired immunodeficiency syndrome	0.00342	0.00484	CcSEcCtD
Fluocinonide—Nervous system disorder—Abacavir—acquired immunodeficiency syndrome	0.00341	0.00482	CcSEcCtD
Fluocinonide—NR3C1—central nervous system—acquired immunodeficiency syndrome	0.0034	0.0123	CbGeAlD
Fluocinonide—Skin disorder—Abacavir—acquired immunodeficiency syndrome	0.00337	0.00477	CcSEcCtD
Fluocinonide—Erythema—Efavirenz—acquired immunodeficiency syndrome	0.0033	0.00467	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Zidovudine—acquired immunodeficiency syndrome	0.00317	0.00449	CcSEcCtD
Fluocinonide—Erythema—Delavirdine—acquired immunodeficiency syndrome	0.00316	0.00447	CcSEcCtD
Fluocinonide—Pruritus—Amprenavir—acquired immunodeficiency syndrome	0.00315	0.00446	CcSEcCtD
Fluocinonide—Pain—Nevirapine—acquired immunodeficiency syndrome	0.00312	0.00442	CcSEcCtD
Fluocinonide—Immune system disorder—Ritonavir—acquired immunodeficiency syndrome	0.00303	0.00428	CcSEcCtD
Fluocinonide—Pain—Nelfinavir—acquired immunodeficiency syndrome	0.00302	0.00428	CcSEcCtD
Fluocinonide—Pain—Stavudine—acquired immunodeficiency syndrome	0.00302	0.00427	CcSEcCtD
Fluocinonide—Nervous system disorder—Zidovudine—acquired immunodeficiency syndrome	0.00301	0.00425	CcSEcCtD
Fluocinonide—Hypersensitivity—Didanosine—acquired immunodeficiency syndrome	0.00299	0.00423	CcSEcCtD
Fluocinonide—Skin disorder—Zidovudine—acquired immunodeficiency syndrome	0.00298	0.00421	CcSEcCtD
Fluocinonide—Pain—Abacavir—acquired immunodeficiency syndrome	0.00297	0.0042	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Indinavir—acquired immunodeficiency syndrome	0.00295	0.00418	CcSEcCtD
Fluocinonide—Immune system disorder—Saquinavir—acquired immunodeficiency syndrome	0.00292	0.00412	CcSEcCtD
Fluocinonide—Pruritus—Didanosine—acquired immunodeficiency syndrome	0.00287	0.00406	CcSEcCtD
Fluocinonide—Erythema—Saquinavir—acquired immunodeficiency syndrome	0.00281	0.00397	CcSEcCtD
Fluocinonide—Rash—Amprenavir—acquired immunodeficiency syndrome	0.00281	0.00397	CcSEcCtD
Fluocinonide—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.00281	0.00397	CcSEcCtD
Fluocinonide—Nervous system disorder—Indinavir—acquired immunodeficiency syndrome	0.00279	0.00395	CcSEcCtD
Fluocinonide—Headache—Amprenavir—acquired immunodeficiency syndrome	0.00279	0.00395	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Efavirenz—acquired immunodeficiency syndrome	0.00279	0.00395	CcSEcCtD
Fluocinonide—Immune system disorder—Lamivudine—acquired immunodeficiency syndrome	0.00278	0.00393	CcSEcCtD
Fluocinonide—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.00277	0.00392	CcSEcCtD
Fluocinonide—NR3C1—brain—acquired immunodeficiency syndrome	0.0027	0.00975	CbGeAlD
Fluocinonide—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.00269	0.00381	CcSEcCtD
Fluocinonide—Erythema—Lamivudine—acquired immunodeficiency syndrome	0.00268	0.00379	CcSEcCtD
Fluocinonide—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.00264	0.00374	CcSEcCtD
Fluocinonide—Pain—Zidovudine—acquired immunodeficiency syndrome	0.00262	0.00371	CcSEcCtD
Fluocinonide—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.00262	0.0037	CcSEcCtD
Fluocinonide—NR3C1—lymph node—acquired immunodeficiency syndrome	0.00261	0.00942	CbGeAlD
Fluocinonide—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.00261	0.00369	CcSEcCtD
Fluocinonide—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.0026	0.00367	CcSEcCtD
Fluocinonide—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.00258	0.00365	CcSEcCtD
Fluocinonide—Rash—Didanosine—acquired immunodeficiency syndrome	0.00256	0.00362	CcSEcCtD
Fluocinonide—Infection—Delavirdine—acquired immunodeficiency syndrome	0.00256	0.00362	CcSEcCtD
Fluocinonide—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.00256	0.00362	CcSEcCtD
Fluocinonide—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.00256	0.00362	CcSEcCtD
Fluocinonide—Headache—Didanosine—acquired immunodeficiency syndrome	0.00254	0.0036	CcSEcCtD
Fluocinonide—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.0025	0.00354	CcSEcCtD
Fluocinonide—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.0025	0.00354	CcSEcCtD
Fluocinonide—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.00249	0.00353	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.00247	0.00349	CcSEcCtD
Fluocinonide—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.00246	0.00348	CcSEcCtD
Fluocinonide—Pain—Indinavir—acquired immunodeficiency syndrome	0.00244	0.00345	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.00238	0.00336	CcSEcCtD
Fluocinonide—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.00234	0.00331	CcSEcCtD
Fluocinonide—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.00234	0.00331	CcSEcCtD
Fluocinonide—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.00233	0.0033	CcSEcCtD
Fluocinonide—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.00231	0.00327	CcSEcCtD
Fluocinonide—Pain—Efavirenz—acquired immunodeficiency syndrome	0.0023	0.00326	CcSEcCtD
Fluocinonide—Rash—Nevirapine—acquired immunodeficiency syndrome	0.0023	0.00326	CcSEcCtD
Fluocinonide—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.0023	0.00325	CcSEcCtD
Fluocinonide—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.0023	0.00325	CcSEcCtD
Fluocinonide—Headache—Nevirapine—acquired immunodeficiency syndrome	0.00229	0.00324	CcSEcCtD
Fluocinonide—Infection—Saquinavir—acquired immunodeficiency syndrome	0.00228	0.00322	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.00227	0.00321	CcSEcCtD
Fluocinonide—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.00225	0.00318	CcSEcCtD
Fluocinonide—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.00223	0.00315	CcSEcCtD
Fluocinonide—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.00223	0.00315	CcSEcCtD
Fluocinonide—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.00223	0.00315	CcSEcCtD
Fluocinonide—Rash—Stavudine—acquired immunodeficiency syndrome	0.00222	0.00314	CcSEcCtD
Fluocinonide—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.00222	0.00314	CcSEcCtD
Fluocinonide—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.00222	0.00313	CcSEcCtD
Fluocinonide—Headache—Stavudine—acquired immunodeficiency syndrome	0.00221	0.00312	CcSEcCtD
Fluocinonide—Pain—Delavirdine—acquired immunodeficiency syndrome	0.0022	0.00312	CcSEcCtD
Fluocinonide—Rash—Abacavir—acquired immunodeficiency syndrome	0.00219	0.0031	CcSEcCtD
Fluocinonide—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.00219	0.0031	CcSEcCtD
Fluocinonide—SMO—GPCRs, Other—ACKR1—acquired immunodeficiency syndrome	0.00218	0.136	CbGpPWpGaD
Fluocinonide—Headache—Abacavir—acquired immunodeficiency syndrome	0.00218	0.00308	CcSEcCtD
Fluocinonide—Infection—Lamivudine—acquired immunodeficiency syndrome	0.00217	0.00307	CcSEcCtD
Fluocinonide—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.00217	0.00307	CcSEcCtD
Fluocinonide—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.00215	0.00303	CcSEcCtD
Fluocinonide—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.00212	0.00301	CcSEcCtD
Fluocinonide—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.0021	0.00297	CcSEcCtD
Fluocinonide—Pain—Ritonavir—acquired immunodeficiency syndrome	0.00204	0.00288	CcSEcCtD
Fluocinonide—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.00203	0.00287	CcSEcCtD
Fluocinonide—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.00202	0.00285	CcSEcCtD
Fluocinonide—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.00198	0.00281	CcSEcCtD
Fluocinonide—Pain—Saquinavir—acquired immunodeficiency syndrome	0.00196	0.00277	CcSEcCtD
Fluocinonide—Rash—Zidovudine—acquired immunodeficiency syndrome	0.00193	0.00273	CcSEcCtD
Fluocinonide—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.00193	0.00273	CcSEcCtD
Fluocinonide—Headache—Zidovudine—acquired immunodeficiency syndrome	0.00192	0.00272	CcSEcCtD
Fluocinonide—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.00191	0.00269	CcSEcCtD
Fluocinonide—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.0019	0.00269	CcSEcCtD
Fluocinonide—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.00188	0.00267	CcSEcCtD
Fluocinonide—Pain—Lamivudine—acquired immunodeficiency syndrome	0.00187	0.00265	CcSEcCtD
Fluocinonide—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.00182	0.00258	CcSEcCtD
Fluocinonide—Rash—Indinavir—acquired immunodeficiency syndrome	0.0018	0.00254	CcSEcCtD
Fluocinonide—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.0018	0.00254	CcSEcCtD
Fluocinonide—Headache—Indinavir—acquired immunodeficiency syndrome	0.00179	0.00253	CcSEcCtD
Fluocinonide—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.00178	0.00252	CcSEcCtD
Fluocinonide—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.00176	0.00248	CcSEcCtD
Fluocinonide—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.0017	0.00241	CcSEcCtD
Fluocinonide—Rash—Efavirenz—acquired immunodeficiency syndrome	0.0017	0.0024	CcSEcCtD
Fluocinonide—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.0017	0.0024	CcSEcCtD
Fluocinonide—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.00169	0.00239	CcSEcCtD
Fluocinonide—Headache—Efavirenz—acquired immunodeficiency syndrome	0.00169	0.00239	CcSEcCtD
Fluocinonide—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.00169	0.00238	CcSEcCtD
Fluocinonide—Rash—Delavirdine—acquired immunodeficiency syndrome	0.00162	0.0023	CcSEcCtD
Fluocinonide—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.00162	0.0023	CcSEcCtD
Fluocinonide—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.00162	0.0023	CcSEcCtD
Fluocinonide—Headache—Delavirdine—acquired immunodeficiency syndrome	0.00161	0.00228	CcSEcCtD
Fluocinonide—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.00161	0.00228	CcSEcCtD
Fluocinonide—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.00158	0.00223	CcSEcCtD
Fluocinonide—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.00155	0.00219	CcSEcCtD
Fluocinonide—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.00152	0.00215	CcSEcCtD
Fluocinonide—Rash—Ritonavir—acquired immunodeficiency syndrome	0.0015	0.00213	CcSEcCtD
Fluocinonide—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.0015	0.00212	CcSEcCtD
Fluocinonide—Headache—Ritonavir—acquired immunodeficiency syndrome	0.00149	0.00211	CcSEcCtD
Fluocinonide—NR3C1—FOXA2 and FOXA3 transcription factor networks—TAT—acquired immunodeficiency syndrome	0.00145	0.0905	CbGpPWpGaD
Fluocinonide—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.00145	0.00205	CcSEcCtD
Fluocinonide—Rash—Saquinavir—acquired immunodeficiency syndrome	0.00145	0.00205	CcSEcCtD
Fluocinonide—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.00144	0.00204	CcSEcCtD
Fluocinonide—Headache—Saquinavir—acquired immunodeficiency syndrome	0.00144	0.00203	CcSEcCtD
Fluocinonide—Rash—Lamivudine—acquired immunodeficiency syndrome	0.00138	0.00195	CcSEcCtD
Fluocinonide—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.00138	0.00195	CcSEcCtD
Fluocinonide—Headache—Lamivudine—acquired immunodeficiency syndrome	0.00137	0.00194	CcSEcCtD
Fluocinonide—SMO—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00102	0.0637	CbGpPWpGaD
Fluocinonide—SMO—GPCRs, Other—CCR5—acquired immunodeficiency syndrome	0.000786	0.049	CbGpPWpGaD
Fluocinonide—SMO—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000618	0.0386	CbGpPWpGaD
Fluocinonide—SMO—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000559	0.0349	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000524	0.0327	CbGpPWpGaD
Fluocinonide—SMO—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000382	0.0238	CbGpPWpGaD
Fluocinonide—SMO—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000346	0.0216	CbGpPWpGaD
Fluocinonide—SMO—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000325	0.0203	CbGpPWpGaD
Fluocinonide—SMO—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000325	0.0203	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000317	0.0198	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000309	0.0193	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000287	0.0179	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—IL10—acquired immunodeficiency syndrome	0.000271	0.0169	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—CSF2—acquired immunodeficiency syndrome	0.000268	0.0167	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—IL4—acquired immunodeficiency syndrome	0.000263	0.0164	CbGpPWpGaD
Fluocinonide—NR3C1—Transcription factor regulation in adipogenesis—TNF—acquired immunodeficiency syndrome	0.00026	0.0162	CbGpPWpGaD
Fluocinonide—NR3C1—FOXA2 and FOXA3 transcription factor networks—ALB—acquired immunodeficiency syndrome	0.000253	0.0158	CbGpPWpGaD
Fluocinonide—SMO—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000247	0.0154	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—IL10—acquired immunodeficiency syndrome	0.000241	0.015	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—CSF2—acquired immunodeficiency syndrome	0.000236	0.0147	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—IL4—acquired immunodeficiency syndrome	0.000232	0.0145	CbGpPWpGaD
Fluocinonide—SMO—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000223	0.0139	CbGpPWpGaD
Fluocinonide—NR3C1—Transcription factor regulation in adipogenesis—IL6—acquired immunodeficiency syndrome	0.00021	0.0131	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000196	0.0122	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000188	0.0117	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000188	0.0117	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	0.000183	0.0114	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000177	0.0111	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.00017	0.0106	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000167	0.0104	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000167	0.0104	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—IFNG—acquired immunodeficiency syndrome	0.000159	0.00993	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—CCNT1—acquired immunodeficiency syndrome	0.000151	0.00944	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	0.000143	0.00889	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—IL2—acquired immunodeficiency syndrome	0.000141	0.00882	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—IFNG—acquired immunodeficiency syndrome	0.00014	0.00875	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000127	0.00791	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000125	0.00779	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—IL2—acquired immunodeficiency syndrome	0.000125	0.00777	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000116	0.00722	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000114	0.00713	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000105	0.00653	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	9.85e-05	0.00614	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	9.85e-05	0.00614	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—IL6—acquired immunodeficiency syndrome	8.32e-05	0.00519	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.49e-05	0.00467	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.38e-05	0.0046	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—IL6—acquired immunodeficiency syndrome	7.33e-05	0.00457	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—CCNT1—acquired immunodeficiency syndrome	7.29e-05	0.00454	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.75e-05	0.00421	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.6e-05	0.00412	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—TNF—acquired immunodeficiency syndrome	6.28e-05	0.00392	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	5.43e-05	0.00338	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—IL6—acquired immunodeficiency syndrome	5.07e-05	0.00316	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	4.38e-05	0.00273	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.9e-05	0.00243	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.88e-05	0.00242	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.29e-05	0.00143	CbGpPWpGaD
